PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143326
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143326
Gamma-Aminobutyric Acid (GABA) Market size was valued at US$ 2,399.6 Million in 2025, expanding at a CAGR of 7.9% from 2026 to 2033.
Gamma-aminobutyric acid, commonly known as GABA, is a non-protein amino acid which is naturally occurring in nature and is also an essential inhibitor neurotransmitter in the central nervous system of developed animals. The most common industrial uses of GABA are its uses as a dietary supplement, functional beverages, sports nutrition, and functional food. The sources of GABA, besides many others, are chemical synthesis, plant enrichment, and microbial fermentation. But the lactic acid bacteria are considered the preferable source since the GABA is directly produced by them through the fermentation of food products. Therefore, growing consumer demand for functional nutrition is driving innovation and expansion in GABA production.
Gamma-Aminobutyric Acid (GABA) Market- Market Dynamics
Rising Anxiety Disorders To Drive Market Demand
The rising prevalence of anxiety disorders is majorly influenced mainly by the increasing demand for more efficient approaches to effectively control the symptoms of anxiety and restore the balance in inhibitory transmission and also by the growing market for GABA products, as GABA is involved with the inhibition of neuronal excitation and associated with anxiety disorders. For instance, in July 2026, according to the Centre for Mental Health Law & Policy (Org), the prevalence of anxiety disorder in India increased by 123.5%, from about 2,592 per 100,000 people to 5,793 per 100,000 people. This data, collected from the use of information and statistics obtained from the Global Burden of Disease (GBD) Study, indicates the exponential increase in the burden of anxiety disorders. This rising burden is accelerating demand for effective GABA-based solutions to manage anxiety symptoms.
The Global Gamma-Aminobutyric Acid (GABA) Market is segmented on the basis of Product Type, Application, Distribution Channel, End User, and Region.
Among the given product types, synthetic GABA is expected to hold a prominent share in the housefly control market because of the greater applicability of synthetic GABA in commercially available insecticides and the proven use of GABA-based insecticides for housefly control purposes. In April 2026, Pharma Foods International introduced its new scientific research about the PharmaGABA(R) ingredient, making it safer and allowing faster implementation into food products, beverages, and dietary supplements. Further clinical research will lead to wider commercial usage of synthetic GABA in the field of nutraceuticals and functional foods along with the applications in pest control that synthetic GABA is already known for. These advancements are expected to strengthen synthetic GABA demand across diverse commercial applications.
Under application, dietary supplements hold a key share in the Gamma-Aminobutyric Acid (GABA) market because of the increasing demand for GABA supplements, which can be used for relaxation, stress management, sleep aid, and calmness. For instance, in June 2025, according to the UK government's National Diet and Nutrition Survey, there were nutritional gaps in a large number of UK citizens, where 96% of the children aged 11-18 and 96% of adults failed to meet the government's requirements for the intake of fiber.
Moreover, there was the prevalence of vitamin D deficiency in 23% of children aged 11-18, as well as 18% of adults aged 19-64; there was the prevalence of low red blood cell folate in 12% of children aged 11-18, 4% of adults aged 19-64, and 2% of adults aged 65 years or above; and 83% of women aged 16-49 had a low value of red blood cell folate, less than 748 nmol/L, where such levels of concentration have been associated with the occurrence of Neural Tube Defects (NTDs). This shows that there are nutritional gaps for various types of nutritional support.
Gamma-Aminobutyric Acid (GABA) Market- Geographical Insights
Asia Pacific maintained a considerable position in the GABA market due to a strong manufacturing base for nutraceuticals, increasing development in the functional foods and drinks market, and growing interest among health consumers in nutraceuticals and food & drinks that support stress & sleeplessness management, mental focus & clarity, and healthy aging. For instance, in February 2025, according to NIH Gov, the use of mental health apps has increased in India due to increasing awareness about mental health problems as well as the availability of smartphones and the internet.
Based on the above analysis, it can be noted that these mental health apps fulfill the needs of the consumers by addressing many conditions and problems such as stress, anxiety, depression & PTSD. They also include various features such as a mood tracker, sleep aids, and virtual therapist sessions. Among the above categories, stress management apps have been recognized as a separate wellness app category, indicating consumer interest in managing stress and wellness problems with the help of smart apps. This indicates consumer interest in managing stress and wellness problems using smart solutions and online applications. This has resulted in rising consumption of GABA wellness and nutraceutical products.
The market for GABA is still fragmented, with competition being determined by specialized producers like Pharma Foods International Co., Ltd., Kyowa Hakko Bio Co., Ltd., Sekisui Chemical Co., Ltd., Zhejiang Yiwan Bio-Technology Co., Ltd., and Bloomage Biotechnology Corporation Limited because of the specialized knowledge they have about fermentation, production processes, and marketing as well as distribution channels. In August 2026, Bloomage Biotechnology was emphasized in industry research due to the exploration of bioactive ingredients, including GABA, in the field of neurocosmetics, and this means that there are still activities in terms of developing GABA-functional and cosmetic solutions. This competitive landscape is expected to intensify as manufacturers expand innovative GABA applications and product portfolios.
In June 2025, Evonik Operations GmbH registered a patent on a new strain of Levilactobacillus brevis that produces GABA, which contributed to the development of fermentation technology for GABA production. The patent application was published in December 2025.